Employers will see private drug plan costs rise by about six per cent annually over the next five years, according to a prediction by a health-care research company.

Brad Millson, principal of health access and outcomes at IQVIA, presented the results of his firm’s 2017-21 forecast, produced in partnership with Innovative Medicines Canada, at Benefits Canada’s 2017 Face-to-Face Drug Plan Management forum on Dec. 14.